Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone ...Middle East

PR Newswire - News
SHENZHEN, China, May 30, 2024 /PRNewswire/ -- On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products...

Hence then, the article about kexing biopharm obtained clinical trial approval for its self developed class i innovative drug long acting growth hormone was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News